Rheumatology Book



Aka: Adalimumab, Humira, Abrilada, Amjevita, Cyltezo, Hulio, Hyrimoz, Yusimry
  1. See Also
    1. Etanercept (Enbrel)
    2. Infliximab (Remicade)
    3. Monoclonal Antibody
  2. Indications
    1. Severe active Rheumatoid Arthritis refractory to DMARDs
    2. Plaque Psoriasis
    3. Crohns Disease
  3. Contraindications
    1. Chronic or acute infection
    2. Concurrent use of Interleukin-1 Receptor Antagonist
      1. Anakinra (Kineret)
  4. Mechanism: Monoclonal Antibody
    1. Human antitumor Necrosis Factor alpha
    2. Similar to Infliximab and Etanercept
  5. Preparations
    1. Humira (Adalimumab)
      1. Original prototype drug with release in 2003 for Rheumatoid Arthritis, with expanding indications since
    2. Multiple biosimilar agents pending release in 2023
      1. Abrilada
      2. Amjevita
      3. Cyltezo
      4. Hulio
      5. Hyrimoz
      6. Yusimry
  6. Dosing
    1. Every other week: 40 mg SC
  7. Adverse Effects
    1. Immunosuppression
      1. Use caution in any patient prone to infection
    2. Headache
    3. Rash
    4. Hypertension
    5. Hyperlipidemia
    6. Injection site inflammation
    7. Gastrointestinal upset
  8. Cost
    1. Two 40 mg vials: $1200 (in 2003)
  9. References
    1. (2003) Lexi-Comp Drug Database
Medication Costs
humira (on 2/22/2017 at Medicaid.Gov Pharmacy Drug pricing)
HUMIRA 40 MG/0.8 ML PEN $2,144.44 each
HUMIRA 40 MG/0.8 ML SYRINGE $2,147.09 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

adalimumab (C1122087)

Definition (NCI) A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.
Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116)
MSH C453439
SnomedCT 398728003, 407317001
LNC LP173592-9, MTHU047400
English adalimumab (medication), tumor necrosis factor alpha blockers adalimumab, ADALIMUMAB, adalimumab [Chemical/Ingredient], antibody d2e7, Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer, D2E7, adalimumab, D2E7 antibody, Adalimumab (product), Adalimumab, Adalimumab (substance)
Spanish adalimumab (producto), adalimumab, adalimumab (sustancia)
Derived from the NIH UMLS (Unified Medical Language System)

Humira (C1171255)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129)
MSH C453439
LNC LA16779-3
English Humira, adalimumab (Humira), humira, Abbott brand of adalimumab
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree